Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Clinical Chemistry|May 25, 2023
Fecal Calprotectin in Gastrointestinal DiseaseJennifer Murray, Klaartje B Kok, Ruth M AylingFrontline Gastroenterology|October 29, 2021
Provision of care for pregnant women with IBD in the UK: the current landscapeSarah Wolloff, Emma Moore, Tracey Glanville, et al.Gastroenterology|July 15, 2015
Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel diseasePaolo Biancheri, Randall J Brezski, Antonio Di Sabatino, et al.Journal of Crohn'S & Colitis|May 10, 2026
Bayesian prior elicitation on the efficacy of medical therapies in perianal fistulizing Crohn's diseaseNurulamin M Noor, Haiyan Zheng, Zhi Cao, et al.Gut|July 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemicNicholas A Kennedy, Malik Janjua, Neil Chanchlani, et al.Gut|April 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDNicholas A Kennedy, Simeng Lin, James R Goodhand, et al.Journal of Crohn'S & Colitis|September 2, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated PatientsNeil Chanchlani, Simeng Lin, Desmond Chee, et al.Gut|March 23, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximabNicholas A Kennedy, James R Goodhand, Claire Bewshea, et al.Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.Gut|June 23, 2025
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025Gordon W Moran, Morris Gordon, Vassiliki Sinopolou, et al.Pageof 2